A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Latest Information Update: 20 Mar 2020
At a glance
- Drugs Iberdomide (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 30 May 2018 Planned End Date changed from 14 Jan 2019 to 24 Sep 2018.
- 30 May 2018 Planned primary completion date changed from 14 Dec 2018 to 24 Aug 2018.